Financial Advocates Investment Management Has $1.17 Million Stake in Stryker Co. (NYSE:SYK)

Financial Advocates Investment Management lowered its holdings in Stryker Co. (NYSE:SYK) by 20.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,251 shares of the medical technology company’s stock after selling 840 shares during the quarter. Financial Advocates Investment Management’s holdings in Stryker were worth $1,171,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. Dunhill Financial LLC raised its holdings in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Darwin Wealth Management LLC bought a new stake in Stryker during the 3rd quarter worth approximately $36,000. Crews Bank & Trust purchased a new stake in shares of Stryker in the fourth quarter worth approximately $39,000. Hara Capital LLC bought a new position in shares of Stryker in the third quarter valued at approximately $42,000. Finally, Grove Bank & Trust boosted its position in shares of Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after buying an additional 56 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.50% of the stock is currently owned by insiders.

Stryker Trading Down 1.2 %

Shares of SYK stock opened at $391.42 on Friday. The stock has a market capitalization of $149.22 billion, a price-to-earnings ratio of 50.44, a PEG ratio of 2.78 and a beta of 0.96. The company’s fifty day simple moving average is $377.25 and its two-hundred day simple moving average is $364.47. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the business posted $3.46 EPS. As a group, analysts anticipate that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio is currently 43.30%.

Analysts Set New Price Targets

Several brokerages have weighed in on SYK. Stifel Nicolaus raised their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Evercore ISI boosted their price target on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Piper Sandler restated an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Finally, UBS Group lifted their price target on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $419.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.